JP2013528650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528650A5 JP2013528650A5 JP2013515459A JP2013515459A JP2013528650A5 JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5 JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5
- Authority
- JP
- Japan
- Prior art keywords
- ylthio
- bromo
- triazol
- acetic acid
- cyclopropylnaphthalen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 51
- -1 4-cyclopropylnaphthalen-1-yl Chemical group 0.000 claims 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 7
- 229960003459 allopurinol Drugs 0.000 claims 7
- 229940116269 uric acid Drugs 0.000 claims 7
- 201000005569 Gout Diseases 0.000 claims 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 4
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 3
- 229960005101 febuxostat Drugs 0.000 claims 3
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 claims 3
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 3
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35500410P | 2010-06-15 | 2010-06-15 | |
| US61/355,004 | 2010-06-15 | ||
| US41144910P | 2010-11-08 | 2010-11-08 | |
| US61/411,449 | 2010-11-08 | ||
| US201161430522P | 2011-01-06 | 2011-01-06 | |
| US61/430,522 | 2011-01-06 | ||
| US201161489420P | 2011-05-24 | 2011-05-24 | |
| US61/489,420 | 2011-05-24 | ||
| PCT/US2011/040398 WO2011159732A1 (en) | 2010-06-15 | 2011-06-14 | Treatment of gout and hyperuricemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528650A JP2013528650A (ja) | 2013-07-11 |
| JP2013528650A5 true JP2013528650A5 (enExample) | 2014-06-05 |
| JP5964821B2 JP5964821B2 (ja) | 2016-08-03 |
Family
ID=45348529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515459A Expired - Fee Related JP5964821B2 (ja) | 2010-06-15 | 2011-06-14 | 痛風と高尿酸血症の処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9216179B2 (enExample) |
| EP (1) | EP2582683B1 (enExample) |
| JP (1) | JP5964821B2 (enExample) |
| CA (1) | CA2802407C (enExample) |
| CY (1) | CY1120473T1 (enExample) |
| DK (1) | DK2582683T3 (enExample) |
| ES (1) | ES2670700T3 (enExample) |
| HR (1) | HRP20180780T1 (enExample) |
| HU (1) | HUE038265T2 (enExample) |
| LT (1) | LT2582683T (enExample) |
| NO (1) | NO2019008I1 (enExample) |
| PL (1) | PL2582683T3 (enExample) |
| PT (1) | PT2582683T (enExample) |
| RS (1) | RS57275B1 (enExample) |
| SI (1) | SI2582683T1 (enExample) |
| SM (1) | SMT201800266T1 (enExample) |
| TR (1) | TR201806828T4 (enExample) |
| WO (1) | WO2011159732A1 (enExample) |
| ZA (1) | ZA201300055B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2794798C (en) | 2010-03-30 | 2017-05-30 | Ardea Biosciences, Inc. | Treatment of gout |
| CA2802407C (en) * | 2010-06-15 | 2018-01-23 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| CA2852490A1 (en) * | 2011-11-03 | 2013-05-10 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound to reduce serum uric acid levels |
| AR091651A1 (es) | 2012-07-03 | 2015-02-18 | Ardea Biosciences Inc | Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico |
| US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| CN103613552A (zh) * | 2013-12-02 | 2014-03-05 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法 |
| US9969701B2 (en) | 2013-12-20 | 2018-05-15 | Crystal Pharmatech Co., Ltd. | Salts and co-crystals of lesinurad |
| CN103755651A (zh) * | 2013-12-23 | 2014-04-30 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法 |
| JP2015160847A (ja) * | 2014-02-28 | 2015-09-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 |
| CN105622531A (zh) | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
| WO2016203436A1 (en) * | 2015-06-19 | 2016-12-22 | Dr. Reddy's Laboratories Limited | Amorphous and amorphous solid dispersion of lesinurad and their preparation |
| EP3112334A1 (en) | 2015-06-29 | 2017-01-04 | DPx Fine Chemicals Austria GmbH & CoKG | Process for manufacturing 1-cyclopropyl-naphthalenes |
| SG11201804100UA (en) * | 2015-12-08 | 2018-06-28 | Ardea Biosciences Inc | Pharmaceutical composition comprising a potent inhibitor of urat1 |
| US12152347B2 (en) | 2018-10-26 | 2024-11-26 | The Procter & Gamble Company | Sanitary tissue product rolls |
| US11633076B2 (en) | 2018-10-26 | 2023-04-25 | The Procter & Gamble Company | Sanitary tissue product rolls |
| CA3060185A1 (en) | 2018-10-26 | 2020-04-26 | The Procter & Gamble Company | Sanitary tissue product rolls |
| US11447916B2 (en) | 2018-10-26 | 2022-09-20 | The Procter & Gamble Company | Paper towel rolls |
| CN114341120A (zh) * | 2019-08-21 | 2022-04-12 | 国立大学法人东京大学 | Abcc11抑制剂 |
| CN110824067B (zh) * | 2019-12-11 | 2024-12-27 | 天津药物研究院有限公司 | 一种非布司他中基因毒性杂质的检测方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE537181T1 (de) | 2003-12-26 | 2011-12-15 | Kissei Pharmaceutical | Benzimidazolderivate und deren medizinische verwendungen |
| US20060189811A1 (en) | 2004-07-23 | 2006-08-24 | Fujiyakuhin Co., Ltd. | Process for producing 1,2,4-triazole compound and intermediate therefor |
| WO2006026356A2 (en) | 2004-08-25 | 2006-03-09 | Ardea Biosciences, Inc. | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| AU2008206231A1 (en) | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| BRPI0819847B1 (pt) | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| US8242154B2 (en) | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN102186832B (zh) | 2008-09-04 | 2014-04-02 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
| US20100160351A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| JP2012527475A (ja) * | 2009-05-20 | 2012-11-08 | アルディア バイオサイエンス，インク． | 尿酸値を調節するための化合物、組成物及び方法 |
| EP2266966A1 (en) | 2009-06-11 | 2010-12-29 | Chemo Ibérica, S.A. | A process for the preparation of febuxostat |
| WO2011085009A2 (en) | 2010-01-08 | 2011-07-14 | Ardea Biosciences, Inc. | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof |
| CA2794798C (en) * | 2010-03-30 | 2017-05-30 | Ardea Biosciences, Inc. | Treatment of gout |
| CA2802407C (en) * | 2010-06-15 | 2018-01-23 | Ardea Biosciences, Inc. | Treatment of gout and hyperuricemia |
| WO2012000103A1 (en) * | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| EP2627331A4 (en) * | 2010-10-15 | 2014-03-12 | Ardea Biosciences Inc | METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES |
| RS55667B1 (sr) | 2010-12-30 | 2017-06-30 | Ardea Biosciences Inc | Polimorfne forme 2-(5-bromo-4-(4-cilkopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) sirćetne kiseline i njihova upotreba |
| CA2837080C (en) | 2011-05-24 | 2017-01-24 | Ardea Biosciences, Inc. | Hypertension and hyperuricemia |
-
2011
- 2011-06-14 CA CA2802407A patent/CA2802407C/en not_active Expired - Fee Related
- 2011-06-14 HR HRP20180780TT patent/HRP20180780T1/hr unknown
- 2011-06-14 HU HUE11796324A patent/HUE038265T2/hu unknown
- 2011-06-14 EP EP11796324.9A patent/EP2582683B1/en not_active Revoked
- 2011-06-14 ES ES11796324.9T patent/ES2670700T3/es active Active
- 2011-06-14 US US13/704,192 patent/US9216179B2/en active Active
- 2011-06-14 JP JP2013515459A patent/JP5964821B2/ja not_active Expired - Fee Related
- 2011-06-14 SI SI201131474T patent/SI2582683T1/en unknown
- 2011-06-14 SM SM20180266T patent/SMT201800266T1/it unknown
- 2011-06-14 DK DK11796324.9T patent/DK2582683T3/en active
- 2011-06-14 RS RS20180571A patent/RS57275B1/sr unknown
- 2011-06-14 PL PL11796324T patent/PL2582683T3/pl unknown
- 2011-06-14 TR TR2018/06828T patent/TR201806828T4/tr unknown
- 2011-06-14 WO PCT/US2011/040398 patent/WO2011159732A1/en not_active Ceased
- 2011-06-14 PT PT117963249T patent/PT2582683T/pt unknown
- 2011-06-14 LT LTEP11796324.9T patent/LT2582683T/lt unknown
-
2013
- 2013-01-03 ZA ZA2013/00055A patent/ZA201300055B/en unknown
-
2015
- 2015-11-12 US US14/939,963 patent/US20160143889A1/en not_active Abandoned
-
2018
- 2018-05-18 CY CY20181100520T patent/CY1120473T1/el unknown
- 2018-09-19 US US16/135,153 patent/US20190015392A1/en not_active Abandoned
-
2019
- 2019-02-19 NO NO2019008C patent/NO2019008I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528655A5 (enExample) | ||
| Grassi et al. | Clinical features of gout | |
| JP5964821B2 (ja) | 痛風と高尿酸血症の処置 | |
| JP2012184234A5 (enExample) | ||
| JP2014532726A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP5649585B2 (ja) | ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物 | |
| Pascual et al. | Febuxostat | |
| JP2013087119A5 (enExample) | ||
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| CA2862602A1 (en) | Therapeutic agent for diabetes | |
| JP6202633B2 (ja) | ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 | |
| JP2018536638A5 (enExample) | ||
| EA028495B1 (ru) | Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина | |
| JP2004534760A (ja) | 腎線維症の治療 | |
| EP3834828B1 (en) | Composition comprising a thiamine derivative for use in the prevention or treatment of vascular or cardiac valve calcification | |
| CN118178378A (zh) | 10-羟基-2-癸烯酸在防治高尿酸血症中的用途 | |
| Ahn et al. | SAT0356 The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout | |
| RU2007133712A (ru) | Способы улучшения распределения лекарственных средств | |
| Wipfler-Freißmuth et al. | Urate oxidase (rasburicase) for treatment of severe acute gout: a case report | |
| KR101647348B1 (ko) | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 | |
| CN108420823A (zh) | 一种选择性抑制痛风结石和尿酸肾结石晶体嘌呤衍生物的应用 | |
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 | |
| JP2019504085A5 (enExample) | ||
| Szczepański et al. | Is Urate-lowering therapy a prevention of first gout episode? |